Novo Nordisk won CFDA approval for its latest diabetes treatment, Tresiba, in China. The Danish company said Tresiba is a once-daily injection that controls blood sugar levels in both type 1 and type 2 diabetics. Novo Nordisk compared Tresiba, an insulin deduglec, to insulin glargines such as Lantus from Sanofi. The two drugs, both injected once-daily, are equally effective, but Tresiba has a lower chance of causing hypoglycemia, it said. Novo Nordisk has long been active in China.
